Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allovectin-7 + dacarbazine
- Development stage
- Unknown
- Lead developer
- Vical
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Gene Therapies, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intratumoral, Intravenous
01
Overview
Allovectin-7 + dacarbazine is a combination therapy studied primarily for the treatment of metastatic melanoma. Allovectin-7 is an investigational gene therapy consisting of a plasmid/lipid complex encoding HLA-B7 and β2 microglobulin, both components of the major histocompatibility complex class I. Its mechanism aims to enhance immune recognition and destruction of cancer cells by increasing their immunogenicity[6][8]. Dacarbazine is a traditional chemotherapy agent classified as an alkylating agent; it works by damaging DNA in cancer cells, leading to cell death. It is used intravenously and has been approved for metastatic melanoma and Hodgkin's lymphoma[1][2][5]. The combination was evaluated in clinical trials for advanced melanoma but did not achieve regulatory approval.
- Brand names
- DTIC-Dome (for dacarbazine)
- Other names
- DTIC (for dacarbazine)DIC (for dacarbazine)imidazole carboxamide (for dacarbazine)
02
Targets
MHC I (MHC class I})DNA
Beyond the preview
Go deeper on Allovectin-7 + dacarbazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allovectin-7 + dacarbazine.